Bladder Cancer VL

The Role of the Surgeon in the Treatment of Bladder Cancer - Jens Bedke

Details
Jens Bedke, MD discusses the multimodal approach for the treatment of bladder cancer from the surgeon's perspective. While cystectomy offers the greatest benefit to most patients, Dr. Bedke emphasizes the importance of differentiating patients, tumor types and tumor grades to guide patient care. Along with the role of neoadjuvant chemotherapy, Dr. Bedke discusses treatment approaches for the varia...

Immunotherapy in the Peri-Operative Setting for Bladder Cancer - Thomas Powles

Details
Thomas Powles, MD, and Charles Ryan, MD share in a discussion regarding the use of immunotherapy in the peri-operative setting for bladder cancer and the current state of immunotherapy for bladder cancer. Dr. Powles, while excited about the evolving role of immunotherapy, is less enthusiastic on the use of combination immune therapy based on recent findings. Monotherapy with either atezolizumab (A...

What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks

Details
Josh Meeks discusses the bladder cancer data from the ASCO GU 2019 meeting that is compelling from the perspective of urologists in this conversation with Alicia Morgans. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of...

ERAS in Bladder Cancer - Sia Daneshmand

Details
Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...

The State of Immunotherapy in Bladder Cancer - Thomas Powles

Details
Thomas Powles discusses the current state of immunotherapy in the treatment of muscle-invasive bladder cancer (MIBC) specifically in the second-line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers a long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clin...

Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits

Details
Jean Hoffman-Censits joins Alicia Morgans and shares details on the Johns Hopkins women’s bladder cancer program. This program is created in recognition of the pathway that women frequently take in the diagnosis of their bladder cancer. We often see a delay in the diagnostic process of bladder cancer in women compared to men. This delay in diagnosis leads to what is thought to be stage migration....

Optimal Surgical Approaches in Cystectomy - Piyush Agarwal

Details
Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan. If you look at the robotic literature in urologic cancers, there is no evidence of any o...

Improving Outcomes in Bladder Cancer - Arnulf Stenzl

Details
Arnulf Stenzl is the co-facilitator of the case-based specialty session. Here he discusses improving outcomes in non-muscle invasive bladder cancer with the en bloc resection for cancers that are smaller than one centimeter which is consistent with the EAU guidelines. Dr. Stenzl has been performing en bloc resections for tumors up to 3 centimeters which provides more information on staging. He als...

The Role of the Surgeon in the Management of Metastatic Bladder Cancer - Brant Inman

Details
Brant Inman discusses the role of the surgeon in the management of metastatic bladder cancer. Oftentimes surgical management is overlooked in favor of systemic therapies, including chemotherapy and immunotherapy. However, in certain cases, a surgical approach may provide a higher cure rate. Dr. Inman and Dr. Kamat discuss appropriate patient selection and scenarios for surgery and the role of neoa...

Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer - Stephen B Williams

Details
Stephen Williams and his team explored the question, what is the association of patient survival and intensity of treatment with total Medicare costs that are associated with radical cystectomy vs trimodal therapy for older adults with localized muscle-invasive bladder cancer in a time frame of longer than 180-days? He and Alicia Morgans discuss the study, its findings, and implications in patient...